Menu Close
The Conversation

Monica Gandhi

5

Articles

13

Comments
Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco

Monica Gandhi MD, MPH is Professor of Medicine and Associate Division Chief (Clinical Operations/ Education) of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital. She also serves as the Director of the UCSF Center for AIDS Research (CFAR) and the Medical director of the HIV Clinic at SFGH ("Ward 86"). Dr. Gandhi completed her M.D. at Harvard Medical School and then came to UCSF in 1996 for residency training in Internal Medicine. After her residency, Dr. Gandhi completed a fellowship in Infectious Diseases and a postdoctoral fellowship at the Center for AIDS Prevention Studies, both at UCSF. She also obtained a Masters in Public Health from Berkeley in 2001 with a focus on Epidemiology and Biostatistics.

Experience

  • –present
    Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco

Education

  • 2001 
    University of California, Berkeley, MPH
  • 1999 
    University of California, San Francisco, Infectious Diseases Fellowship
  • 1996 
    University of California, San Francisco, Residency
  • 1996 
    Harvard Medical School, M.D.

Publications

  • 2019
    Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial, Clinical Infectious Diseases
  • 2019
    Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cut-Off for a Point-of-Care Test, JAIDS
  • 2019
    Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a PrEP demonstration project, AIDS
  • 2019
    RAPID ART: High virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population, AIDS
  • 2018
    Degree of Housing Instability Shows Independent “Dose-Response” with Virologic Suppression Rates among People Living with HIV, Open Forum Infectious Diseases
  • 2018
    Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence, The Lancet
  • 2016
    HIV Pre-Exposure Prophylaxis for Women, Journal of Virus Eradication

Grants and Contracts

  • 2020
    Objective measures of adherence for later-stage ART failure in resource limited settings
    Role:
    PD/PI
    Funding Source:
    National Institute of Allergy and Infectious Diseases
  • 2019
    Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in
    Role:
    PD/PI
    Funding Source:
    National Institute of Allergy and Infectious Diseases
  • 2018
    Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP
    Role:
    PD/PI
    Funding Source:
    National Institute of Allergy and Infectious Diseases
  • 2017
    Hair Extensions;: Using Hair Levels to Interpret Adherence, Effectiveness and Pharmacokinetics with Real-World Oral PrEP, the Vaginal Ring, and
    Role:
    PD/PI
    Funding Source:
    National Institute of Allergy and Infectious Diseases
  • 1997
    UCSF-GIVI Center for AIDS Research (CFAR)
    Role:
    PD/PI
    Funding Source:
    National Institute of Allergy and Infectious Diseases